Complete response rate in Nektar melanoma trial hits 34%
04 Jun 2019 //
FIERCE BIOTECH
OncoSec announces triple combo trial of TAVO, Epacadostat & Keytruda
24 Apr 2019 //
PHARMABIZ
Nektar`s Sole Skeptic Warns of Parallels to Biggest Biotech Flop
05 Jun 2018 //
BLOOMBERG